{
  "id": 20484834,
  "title": "Why don't GLP‑1 obesity drugs work for everyone?",
  "url": "https://urgent.news/2026/11/17/why-dont-glp-1-obesity-drugs-work-for-everyone",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-17T20:00:15.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-dont-glp1-obesity-drugs.html"
  },
  "original_language": "en",
  "account": "GLP‑1 obesity drugs like Ozempic and Wegovy, which contain semaglutide, have gained prominence in managing obesity. Semaglutide works by acting on the brain to reduce appetite and increase feelings of fullness. However, these medications do not work uniformly for everyone. The University of Alberta is conducting research to understand why some individuals respond better to semaglutide than others and how to maintain weight loss over time. They are investigating energy metabolism as a crucial factor in this variability. Energy metabolism refers to the balance between calories consumed and calories burned, including processes like breathing, thinking, and digestion. When weight is lost, the body's energy needs decrease. However, some people experience metabolic adaptation, where their bodies burn even fewer calories than expected. This can make continued weight loss more challenging. The researchers are also exploring how factors such as genetics, metabolism, body composition, lifestyle, and microbiota influence individual responses to GLP‑1 medications. They are particularly interested in understanding whether semaglutide affects resting energy use differently, which could provide insights into why some people do not respond to treatment. The University of Alberta has a specialized facility called a whole-room indirect calorimeter to measure energy utilization accurately. They are enrolling participants with blood sugar regulation issues who are about to start semaglutide treatment. Over six months, they will monitor changes in weight, body composition, and energy utilization. Understanding how semaglutide influences energy use and body composition could help develop more personalized approaches to obesity and type 2 diabetes management. In the meantime, individuals taking or considering semaglutide should make lifestyle changes such as improving nutrition, eating consistent portions, avoiding skipping meals, engaging in resistance exercise, and staying hydrated. These strategies may help mitigate reductions in energy use as weight is lost.",
  "summary": "Medications like Ozempic and Wegovy, which contain semaglutide—a GLP‑1 receptor agonist that helps regulate blood sugar, appetite and body weight—have become household names and important pillars in obesity management for the medical profession.",
  "key_points": [
    "GLP‑1 drugs like Ozempic and Wegovy reduce appetite and increase fullness.",
    "University of Alberta researching why some people respond better to semaglutide.",
    "Metabolic adaptation and individual factors influence weight loss success."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}